Skip to main content
Back
IART logo

Integra LifeSciences Holdings Corporation

Data quality: 100%
IART
NASDAQ Healthcare Medical - Devices
$9.43
▲ $0.49 (5.48%)
Mkt Cap: 734.95M
Day Range
$9.11 $9.62
52-Week Range
$8.70 $22.96
Volume
1,053,748
50D / 200D Avg
$11.06 / $12.79
Prev Close
$8.94

Price History

Financial Trends

Peer Comparison

vs Healthcare sector median (626 peers)

Metric Stock Sector Median
P/E -1.4 0.4
P/B 0.7 2.9
ROE % -39.9 3.7
Net Margin % -31.6 3.8
Rev Growth 5Y % 1.5 10.0
D/E 2.0 0.2

Insider Trading Activity

20 transactions
Date Insider Type Shares Price Value
Mar 11, 2026
Hutchinson Michael Damon
EVP, Chief Legal Officer & Sec
grant 70,305
Mar 11, 2026
Knight Lea Daniels
EVP & Chief Financial Officer
other 8,089 $9.61 $77,735
Mar 11, 2026
Knight Lea Daniels
EVP & Chief Financial Officer
grant 111,179
Mar 11, 2026
DAVIS ROBERT T. JR.
EVP & President, TT
other 8,487 $9.61 $81,560
Mar 11, 2026
DAVIS ROBERT T. JR.
EVP & President, TT
grant 43,350
Mar 11, 2026
McBreen Michael J.
EVP & President, CSS
other 7,247 $9.61 $69,644
Mar 11, 2026
McBreen Michael J.
EVP & President, CSS
grant 92,108
Mar 10, 2026
DAVIS ROBERT T. JR.
EVP & President, TT
other 687 $9.55 $6,561
Mar 10, 2026
McBreen Michael J.
EVP & President, CSS
other 2,354 $9.55 $22,481
Feb 2, 2026
Hutchinson Michael Damon
EVP, Chief Legal Officer & Sec
grant 89,606
Nov 5, 2025
GRAVES JEFFREY A
Director
buy 9,000 $11.35 $102,150
Oct 12, 2025
Singh Harvinder
EVP & PRESIDENT, INTERNATIONAL
other 27,211
Jul 3, 2025
Mosebrook Jeffrey
SVP, Fin & Princ Acct Officer
other 3,345 $13.49 $45,124
Jul 3, 2025
Knight Lea Daniels
EVP & Chief Financial Officer
other 2,561 $13.49 $34,548
Jul 1, 2025
Mosebrook Jeffrey
SVP, Fin & Princ Acct Officer
other 937 $13.25 $12,415
May 9, 2025
BRADLEY KEITH
Director
other 392 $12.25 $4,802
May 9, 2025
BRADLEY KEITH
Director
grant 19,592
May 9, 2025
HILL BARBARA B
Director
grant 26,531
May 9, 2025
Clay Shaundra
Director
grant 19,592
May 9, 2025
Lo Renee Wonlai
Director
grant 19,592

Key Takeaways

Revenue grew 1.47% annually over 5 years — modest growth
Negative free cash flow of -31.05M
Capital efficient — spends only 4.98% of revenue on capex
ROIC of 1.67% — low return on invested capital
Interest coverage of 0.79× — tight debt servicing

Growth

Revenue Growth (5Y)
1.47%
Revenue (1Y)1.53%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
-39.90%
ROIC1.67%
Net Margin-31.58%
Op. Margin4.18%

Safety

Debt / Equity
1.95
Current Ratio2.54
Interest Coverage0.79

Valuation

P/E Ratio
-1.42
P/B Ratio0.70
EV/EBITDA37.08
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 1.53% Revenue Growth (3Y) 2.99%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 1.47% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 1.64B Net Income (TTM) -516.47M
ROE -39.90% ROA -14.34%
Gross Margin 51.69% Operating Margin 4.18%
Net Margin -31.58% Free Cash Flow (TTM) -31.05M
ROIC 1.67% FCF Growth (3Y) N/A
Safety
Debt / Equity 1.95 Current Ratio 2.54
Interest Coverage 0.79 Dividend Yield 0.00%
Valuation
P/E Ratio -1.42 P/B Ratio 0.70
P/S Ratio 0.45 PEG Ratio 0.00
EV/EBITDA 37.08 Dividend Yield 0.00%
Market Cap 734.95M Enterprise Value 2.53B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 1.64B 1.61B 1.54B 1.56B 1.54B
Net Income -516.47M -6.94M 67.74M 180.55M 169.08M
EPS (Diluted) -6.73 -0.09 0.84 2.16 1.98
Gross Profit 845.23M 882.06M 884.74M 970.31M 944.64M
Operating Income 68.32M 28.41M 111.53M 238.92M 197.23M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 3.60B 4.04B 3.78B 3.89B 3.78B
Total Liabilities 2.56B 2.49B 2.19B 2.09B 2.10B
Shareholders' Equity 1.04B 1.55B 1.59B 1.80B 1.68B
Total Debt 2.03B 1.98B 1.68B 1.63B 1.67B
Cash & Equivalents 235.05M 246.38M 276.40M 456.66M 513.45M
Current Assets 1.16B 1.08B 1.06B 1.16B 1.15B
Current Liabilities 455.98M 922.13M 306.98M 320.91M 340.02M